The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global sickle cell disease treatment market was valued at US$ 2.6 Billion in 2021.
We expect the global sickle cell disease treatment market to exhibit a CAGR of 16.0% during 2022-2027.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective treatment procedures for sickle cell disease to reduce the risk of the coronavirus infection upon hospital visits and interaction with healthcare professionals or medical equipment.
The rising prevalence of sickle cell disease, along with the growing demand for new medications that can treat the condition effectively, to reduce specific symptoms and prolong the life of patients, is primarily driving the global sickle cell disease treatment market.
Based on the treatment type, the global sickle cell disease treatment market has been segregated into blood transfusion, pharmacotherapy, and bone marrow transplant. Among these, blood transfusion currently holds the largest market share.
Based on the end user, the global sickle cell disease treatment market can be bifurcated into hospitals, diagnostic centers, and others. Currently, hospitals exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global sickle cell disease treatment market include AstraZeneca Plc, Baxter International Inc., bluebird bio Inc., Bristol-Myers Squibb Company, CRISPR Therapeutics, Emmaus Medical Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Novartis AG, Pfizer Inc., and Sangamo Therapeutics.
Swine Healthcare Market by Product (Diagnostic Tests, Therapeutics), Disease (Exudative Dermatitis, Coccidiosis, Respiratory Diseases, Swine Dysentery, Porcine Parvovirus, and Others), Route of Administration (Injectable, Oral), Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Online Pharmacy), and Region 2023-2028
Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2023-2028
Congestive Heart Failure Drugs Market by Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2023-2028
Gastric Cancer Drugs Market by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at